4 results
8-K
EX-99.2
CGTX
Cognition Therapeutics Inc
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
: 66.4 years 50% Female 100% White, non-Hispanic Baseline cognitive measures: - Mean MMSE: 21.1 - ADAS-Cog14: 30.2 - Amsterdam IADL: 52.6 ApoE genotypes
DEF 14A
CGTX
Cognition Therapeutics Inc
25 Apr 22
Definitive proxy
5:28pm
Hispanic or Latinx
Native Hawaiian or Pacific Islander
White
Two or More Races or Ethnicities
LGBTQ+
Did Not Disclose Demographic Background
Potential
- Prev
- 1
- Next